Today, we are honored to host Dr. Sara Naseri, CEO and Co-Founder of Qvin, a pioneering figure in women’s health innovation. In this session, we will explore the groundbreaking Q-Pad technology, the ...
The Phase 3 PATINA Trial shows that adding palbociclib (IBRANCE®) to standard maintenance therapy significantly extends ...
The latest findings presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) reveal that patients with germline BRCA ...
AbbVie has announced plans to acquire Nimble Therapeutics in a $200 million deal. The acquisition brings Nimble’s pioneering ...
Nektar Therapeutics announced promising results from a Phase 2 study of its experimental drug NKTR-255, which improved ...
Imlunestrant, an oral SERD, significantly prolonged progression-free survival in patients with advanced ER+, HER2- breast ...
Merck has announced that the Phase 3 KEYLYNK-001 trial demonstrated that KEYTRUDA® (pembrolizumab) combined with chemotherapy ...
The DREAMM-7 trial shows belantamab mafodotin combined with bortezomib and dexamethasone significantly improves overall ...
General Inception, a global biotech company igniter, has acquired Enable Medicine, a leader in Artificial Intelligence-driven ...
The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival ...
FDA has granted accelerated approval to Bizengri® (zenocutuzumab-zbco), a first-in-class bispecific antibody targeting NRG1+ ...
Adding Blinatumomab to Chemotherapy Extends 96% Disease-Free Survival in Pediatric Leukemia Patients
Adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves three-year disease-free survival (96%) in children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback